Skip to main content

Table 2 Cell-Type Distinguishing Genes Most Highly Elevated by RT

From: Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab

 

18w Fc vs noRT

30w Fc vs noRT

Gene ID

Description

RT

RT + FG

RT

RT + FG

Mast Cell

 Mcpt4

mast cell protease 4

109.9

5.9

10.7

2.2

 Cpa3

carboxypeptidase A3, mast cell

94.2

3.3

19.9

3.0

 Cma2

chymase 2, mast cell protease 9

51.6

3.6

9.0

2.0

 Cma1

chymase 1, mast cell

46.5

2.7

4.8

1.1

 Tpsg1

tryptase gamma 1, mast cell protease 2

22.7

2.7

40.2

5.0

 Mrgprb1

MAS-related GPR, member B1

20.3

2.9

8.5

1.7

 Darc

Duffy blood group, chemokine receptor

18.5

1.9

2.3

0.9

 Tpsb2

tryptase beta 2, mast cell protease 6

18.0

2.5

5.5

3.8

Macrophage

 Mmp12

matrix metallopeptidase 12

24.0

0.4

6.0

1.2

 Trem2

triggering receptor expressed on myeloid cells 2

15.5

1.4

7.0

1.6

 Msr1

macrophage scavenger receptor 1

10.0

0.5

5.1

1.2

 Cd200r1

CD200 receptor 1

7.1

1.0

3.1

1.1

 Ccl3

chemokine ligand 3

6.9

0.8

1.3

0.4

 Ms4a7

membrane-spanning 4-domains, subfamily A, member 7

6.8

1.0

2.5

0.9

 Fcgr2b

Fc receptor, IgG, low affinity IIb

6.6

0.7

2.2

1.3

 Ms4a6d

membrane-spanning 4-domains, subfamily A, member 6D

6.5

0.4

2.4

1.2

Dendritic Cell

 Cxcl9

chemokine (C-X-C motif) ligand 9

79.8

4.0

1.1

0.5

 Kynu

kynureninase

6.5

0.8

2.3

1.3

 Dnase1l3

deoxyribonuclease 1-like 3

5.6

2.5

0.9

1.0

 Serpina3g

serine peptidase inhibitor, clade A, member 3G

5.3

1.1

1.6

1.1

 Ppfia4

protein tyrosine phosphatase, f polypeptide, interacting, a4

5.1

1.3

2.5

1.3

 Ffar2

free fatty acid receptor 2

4.1

1.8

1.8

0.9

 Itgax

integrin alpha X

4.1

0.7

1.9

0.8

 Ccl5

chemokine (C-C motif) ligand 5

3.9

1.7

0.9

0.8

Mesenchymal Cell

 Dlk1

delta-like 1 homolog (Drosophila)

15.2

4.7

26.3

10.4

 Timp1

tissue inhibitor of metalloproteinase 1

8.2

0.4

3.6

0.8

 Fn1

fibronectin 1

7.4

1.3

3.9

1.7

 Wisp1

WNT1 inducible signaling pathway protein 1

5.3

0.9

2.4

1.5

 Ptx3

pentraxin related gene

4.7

1.1

1.6

1.2

 Col5a2

collagen, type V, alpha 2

4.5

0.6

1.7

1.1

 Wisp2

WNT1 inducible signaling pathway protein 2

4.0

0.9

2.7

1.3

 Fstl1

follistatin-like 1

4.0

1.0

2.4

1.3

Neutrophil

 Clec7a

C-type lectin domain family 7, member a

6.0

0.7

1.5

0.6

 Aif1

allograft inflammatory factor 1

4.1

1.1

2.0

1.1

 Ffar2

free fatty acid receptor 2

4.1

1.8

1.8

0.9

 P2ry13

purinergic receptor P2Y, G-protein coupled 13

2.7

0.4

1.3

0.9

 Fpr1

formyl peptide receptor 1

2.4

0.7

1.6

0.8

 Lst1

leukocyte specific transcript 1

2.3

0.8

1.1

0.8

 Mnda

myeloid cell nuclear differentiation antigen

2.1

1.5

1.5

1.1

B-cell

 Igl-V1

immunoglobulin lambda chain (IgL) mRNA

8.0

1.2

0.7

1.4

 March1

membrane-associated ring finger (C3HC4) 1

3.3

1.1

1.7

1.3

 Ulbp1

UL16 binding protein 1

3.3

0.7

1.8

1.3

 Cd22

CD22 antigen

3.0

2.4

1.3

1.3

 H2-DMb2

histocompatibility 2, class II, locus Mb2

2.8

1.1

0.9

1.3

 Tlr1

toll-like receptor 1

2.7

1.0

1.1

1.1

 Mef2c

myocyte enhancer factor 2C

2.2

1.7

1.5

0.9

Endothelial Cell

 Col4a1

collagen, type IV, alpha 1

3.20

0.6

1.82

1.2

 Col4a2

collagen, type IV, alpha 2

3.11

0.5

1.76

1.2

 Fabp4

fatty acid binding protein 4, adipocyte

3.01

1.2

1.73

0.5

 Mgp

matrix Gla protein

2.07

0.7

1.39

1.1

Multiple Potential Cell Sources

 Ankrd34b

ankyrin repeat domain 34B

224.3

8.9

8.9

1.1

 Chl1

cell adhesion molecule with homology to L1CAM

93.8

1.3

15.6

1.0

 Ucma

upper zone of growth plate and cartilage matrix associated

71.2

1.8

9.9

1.2

 Tnfsf18

tumor necrosis factor (ligand) superfamily, member 18

46.8

3.6

2.8

1.0

 Gdf3

growth differentiation factor 3

32.1

3.9

4.2

1.1

 Ear5

eosinophil-associated, ribonuclease A family, member 5

29.5

2.1

18.3

1.6

 Ccl8

chemokine (C-C motif) ligand 8

29.0

2.0

5.4

0.9

 Dio3

deiodinase, iodothyronine type III

25.6

1.4

10.3

1.1

  1. Fold-change (Fc) values are relative to unirradiated (noRT) controls for RT alone and RT + FG-3019 (FG) treatment begun 16 weeks after RT